RO 6958948

Drug Profile

RO 6958948

Alternative Names: 18F-labelled RO 6958948; [18F]RO 6958948; RO6958948

Latest Information Update: 31 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Roche
  • Class Imaging agents; Monoclonal antibody diagnostics; Radiopharmaceutical diagnostics; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters; Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease

Most Recent Events

  • 31 Mar 2017 Phase-II clinical trials in Alzheimer's disease (Diagnosis) in Sweden (IV) (EudraCT2017-000094-36)
  • 01 Jul 2016 Roche initiates a phase I follow-up trial in Alzheimer's disease (Diagnosis) in USA (NCT02792179)
  • 02 Jun 2016 Roche plans a phase I follow-up trial in Alzheimer's disease (Diagnosis) in USA (NCT02792179)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top